Cargando…
LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer
PURPOSE: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. PATIENTS AND METHODS: The association between LpMab-23-recognizing cancer-type PDPN expression and clinical/pathological featur...
Autores principales: | Miyazaki, Akihiro, Nakai, Hiromi, Sonoda, Tomoko, Hirohashi, Yoshihiko, Kaneko, Mika K., Kato, Yukinari, Sawa, Yoshihiko, Hiratsuka, Hiroyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940393/ https://www.ncbi.nlm.nih.gov/pubmed/29765527 http://dx.doi.org/10.18632/oncotarget.24986 |
Ejemplares similares
-
Characterization of Monoclonal Antibody LpMab-3 Recognizing Sialylated Glycopeptide of Podoplanin
por: Oki, Hiroharu, et al.
Publicado: (2015) -
LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin
por: Kato, Yukinari, et al.
Publicado: (2016) -
A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models
por: Suzuki, Hiroyuki, et al.
Publicado: (2023) -
A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin
por: Kato, Yukinari, et al.
Publicado: (2014) -
Antitumor activity of chLpMab‐2, a human–mouse chimeric cancer‐specific antihuman podoplanin antibody, via antibody‐dependent cellular cytotoxicity
por: Kaneko, Mika K., et al.
Publicado: (2017)